

Press release from Extraordinary General Meeting of Cereno Scientific AB

An Extraordinary General Meeting of Cereno Scientific AB (“Cereno”) was held today, 29 September 2020, at the premises of University of Gothenburg, Universitetsplatsen 1, Gothenburg, Sweden. A summary of the resolutions made is presented below. All resolutions were unanimous.

Resolution on changes to the Articles of Association

The Meeting resolved, in accordance with the proposal from the Board of Directors, to adopt new Articles of Association with amended limits for share capital and the number of shares, as a result of which the Articles of Association have been amend as follows.

Article 4 – Share capital

Previous wording (prior to the Meeting):

The share capital shall be not less than SEK 1,900,000 and not more than SEK 7,600,000.

New wording:

The share capital shall be not less than SEK 4,000,000 and not more than SEK 16,000,000.

Article 5 – Number of shares

Previous wording (prior to the Meeting):

The number of shares in the Company shall be not less than 19,000,000 and not more than 76,000,000.

The rest of article 5 is left unchanged.

New wording:

The number of shares in the Company shall be not less than 40,000,000 and not more than 160,000,000.

Resolution on adjustment authorization

The Meeting resolved to authorise the Board, the CEO, or the party appointed by the Board in its place, to make minor adjustments to resolutions made by the Meeting that may be necessary in connection with registration with the Swedish Companies Registration Office and Euroclear Sweden AB.

For further information, please contact:

Daniel Brodén – CFO

Tel: +46 768 66 77 87

E-mail: info@cerenoscientific.com

www.cerenoscientific.se

About Cereno Scientific AB

Cereno Scientific is developing a pipeline of preventive therapeutics to treat cardiovascular and rare diseases by epigenetic modulation through histone deacetylase inhibition (HDACi). The company's

lead program, CS1, is a phase II dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation. Cereno Scientific also evaluates the potential of epigenetic modulation for rare diseases related to pulmonary fibrosis, thrombosis, inflammation and high blood pressure in the pulmonary circulation system. The FDA has granted ODD for the indication Pulmonary Arterial Hypertension (PAH) to the company's lead compound CS1. Cereno Scientific also has a preclinical HDAC inhibitor development program. The company is located in AstraZeneca's BioVenture Hub. Cereno Scientific's B share has been listed on Spotlight Stock market since June 2016 with the ticker CRNO B, ISIN SE0008241558.